Production (Stage)
Fulcrum Therapeutics, Inc.
FULC
$6.85
$0.071.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 80.00M | 80.00M | 80.87M | 81.63M | 2.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 80.00M | 80.00M | 80.87M | 81.63M | 2.51M |
| Cost of Revenue | 57.02M | 63.39M | 70.67M | 74.27M | 74.86M |
| Gross Profit | 22.98M | 16.61M | 10.20M | 7.36M | -72.35M |
| SG&A Expenses | 33.39M | 36.45M | 38.60M | 40.13M | 40.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.40M | 99.83M | 109.27M | 114.40M | 115.07M |
| Operating Income | -10.40M | -19.83M | -28.40M | -32.77M | -112.56M |
| Income Before Tax | -510.00K | -9.73M | -17.91M | -20.23M | -99.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.51 | -9.73 | -17.91 | -20.23 | -99.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -510.00K | -9.73M | -17.91M | -20.23M | -99.43M |
| EBIT | -10.40M | -19.83M | -28.40M | -32.77M | -112.56M |
| EBITDA | -8.94M | -18.24M | -26.67M | -30.88M | -110.47M |
| EPS Basic | -0.05 | -0.20 | -0.29 | -0.33 | -1.61 |
| Normalized Basic EPS | -0.01 | -0.10 | -0.16 | -0.21 | -1.00 |
| EPS Diluted | -0.07 | -0.22 | -0.31 | -0.35 | -1.61 |
| Normalized Diluted EPS | -0.02 | -0.11 | -0.17 | -0.22 | -1.00 |
| Average Basic Shares Outstanding | 241.05M | 240.55M | 248.47M | 247.88M | 247.47M |
| Average Diluted Shares Outstanding | 242.43M | 241.93M | 249.85M | 249.27M | 247.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |